MASSDEVICE ON CALL — Federal officials this week will vote on a measure that aims to set aside a key radio spectrum for use by medical devices.
If approved, the radio spectrum will be designated for devices employing "mobile body area networks," using wireless communication to allow multiple devices to communicate within and around the body.
The technology may be used for products that continuously monitor vital signs, potentially doing away with the web of cords and wires that generally accompanies hospital care.
The spectrum in question ranges from 2.36 GHz to 2.4 GHz, and would be shared with aerospace manufacturers and the government, which currently uses the spectrum to test aircraft and missiles, GovHealthIT.com reported. The vote is set for May 24.
Device makers won another key radio radio spectrum late last year, between 413 mHz and 457 mHz, for use in Medical Micropower Networks that transmit radio signals among multiple microstimulators implanted in the body to activate and monitor nerves and muscles with electrical signals.
Such devices could help patients regain functionality and sensation in paralyzed limbs, Alfred Mann Foundation CEO David Hankin told MassDevice.com late last year.
15-year-old wins Intel science fair with non-invasive pancreatic cancer test
15-year-old Jack Andraka of Maryland won 1st prize and $75,000 in the Intel International Science & Engineering fair by developing a non-invasive early-detection tool for pancreatic cancer.
Microsoft’s Kinect gaming controller debuts in the OR
Microsoft’s Kinect gaming sensor, which turns the body into a controller through hyper-resolution visual tracking, made its way into the operating room as the company plays around with ways the device can help in surgery.
Electronic tattoo wins Gates grant
A wearable electronic patch that attached to skin like a temporary tattoo won a grant from the Bill & Melinda Gates Foundation as a prospective means of continuously monitoring vital signs in pregnant women and fetuses.
Allergan adds a new facility, 400 jobs in New Jersey
Aesthetic devices maker Allergan (NYSE:AGN) announced plans to build a $12 million R&D facility in Bridgewater, N.J., where it expects to add 400 new jobs.